サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1720870

処方皮膚科治療薬の世界市場レポート 2025年

Prescription Dermatological Drugs Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.63円
処方皮膚科治療薬の世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

処方皮膚科治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.7％で、522億7,000万米ドルに成長します。この予測期間における成長は、皮膚疾患の有病率の増加、皮膚科の健康に対する意識の高まり、皮膚科受診のための遠隔医療導入の拡大、スキンケア美容に対する需要の高まり、皮膚科治療に対する保険適用の強化、個別化医療と精密皮膚科学への注目の高まりによってもたらされると予想されます。主要動向としては、標的生物学的療法の開発、皮膚疾患に対する遺伝子編集の採用、ドラッグデリバリーシステムの進歩、遺伝子プロファイリングによる個別化治療、外用薬の吸収改善、薬剤配合と治療計画を最適化するための人工知能の統合などが挙げられます。

皮膚疾患の有病率の増加は、処方皮膚科治療薬市場の拡大を促進すると予想されます。皮膚科疾患には、湿疹、乾癬、にきびなど、皮膚、毛髪、爪に影響を及ぼす疾患が含まれ、効果的な症状管理のためには治療が必要です。これらの疾患の発生が増加しているのは、環境汚染物質への曝露の増加、ライフスタイルの変化、ストレスレベルの上昇が主要原因です。処方皮膚科治療薬は、症状を緩和し、長期的な皮膚の健康を促進するための標的治療を提供することにより、これらの症状を管理する上で重要な役割を果たしています。例えば、2022年3月、EMBLの生物医療研究のための欧州バイオインフォマティクスラボが主催する英国の組織であるEurope PubMed Centralは、欧州27カ国で実施された調査で、約1億8,500万人に相当する参加者の約43.35％が少なくとも1つの皮膚疾患を経験しており、真菌感染症、アトピー性皮膚炎、にきびが最も多いことを報告しました。その結果、皮膚疾患の有病率の増加が処方皮膚科治療薬市場の成長を促進しています。

処方皮膚科治療薬市場の主要企業は、アンメット・メディカル・ニーズに対応し、慢性的で治療困難な皮膚疾患に悩む患者により効果的なソリューションを提供するため、結節性痒疹の治療法などの革新的治療法の開発を優先しています。結節性痒疹は、強い痒み、盛り上がり、硬い結節や隆起を特徴とする慢性皮膚疾患です。例えば、2022年9月、米国のバイオテクノロジー企業であるリジェネロン・ファーマシューティカルズインクは、フランスの製薬会社であるSanofiS.A.と提携し、デュピクセント（デュピルマブ）の米国食品医薬品局（FDA）からの承認を取得しました。これにより、結節性痒疹の治療として初めてFDAに承認された唯一の治療となります。今回の承認は、デュピクセントを投与された患者において、プラセボを投与された患者と比較して、かゆみの程度と皮膚病変が有意に改善したことを示す臨床検査データに基づいています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の処方皮膚科治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の処方皮膚科治療薬市場：成長率分析
  • 世界の処方皮膚科治療薬市場の実績：規模と成長、2019～2024年
  • 世界の処方皮膚科治療薬市場の予測：規模と成長、2024～2029年、2034年
  • 世界の処方皮膚科治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の処方皮膚科治療薬市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
  • コルチコステロイド
  • レチノイド
  • カルシニューリン阻害剤
  • 抗真菌剤
  • 抗生物質
  • その他
  • 世界の処方皮膚科治療薬市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
  • ニキビ
  • 乾癬
  • 皮膚炎
  • 真菌性皮膚感染症
  • その他
  • 世界の処方皮膚科治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他
  • 世界の処方皮膚科治療薬市場、コルチコステロイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 局所コルチコステロイド
  • 経口コルチコステロイド
  • 注射用コルチコステロイド
  • 世界の処方皮膚科治療薬市場、レチノイドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 局所レチノイド
  • 経口レチノイド
  • 世界の処方皮膚科治療薬市場、カルシニューリン阻害剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 局所カルシニューリン阻害剤
  • 経口カルシニューリン阻害剤
  • 世界の処方皮膚科治療薬市場、抗真菌剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 局所抗真菌薬
  • 経口抗真菌薬
  • 世界の処方皮膚科治療薬市場、抗生物質のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 局所抗生物質
  • 経口抗生物質
  • 世界の処方皮膚科治療薬市場、その他の薬剤クラスのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 免疫抑制剤
  • 光線療法剤

第7章 地域別・国別分析

  • 世界の処方皮膚科治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の処方皮膚科治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 処方皮膚科治療薬市場：競合情勢
  • 処方皮膚科治療薬市場：企業プロファイル
    • Pfizer Inc.
    • Johnson & Johnson
    • Merck KGaA
    • AbbVie Inc.
    • Bayer AG

第31章 その他の大手企業と革新的企業

  • Novartis AG
  • GSK plc
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Cadila Health Care Limited
  • Leo Pharma A/S
  • Glenmark Pharmaceuticals Limited
  • Almirall S.A.
  • DermBiont Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 処方皮膚科治療薬市場、2029年：新たな機会を提供する国
  • 処方皮膚科治療薬市場、2029年：新たな機会を提供するセグメント
  • 処方皮膚科治療薬市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34128

Prescription dermatological drugs are medications prescribed by healthcare providers to treat various skin conditions, including acne, eczema, psoriasis, and other dermatological disorders. These drugs contain active ingredients that require medical supervision to ensure safe and effective use.

The primary drug classes of prescription dermatological drugs include corticosteroids, retinoids, calcineurin inhibitors, antifungal agents, antibiotics, and others. Corticosteroids, which are steroid hormones derived from the adrenal cortex or their synthetic analogs, are primarily used to reduce inflammation and suppress immune responses in various medical conditions. These medications are commonly prescribed for conditions such as acne, psoriasis, dermatitis, and fungal skin infections. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The prescription dermatological drugs market research report is one of a series of new reports from The Business Research Company that provides prescription dermatological drugs market statistics, including the prescription dermatological drugs industry's global market size, regional shares, competitors with a prescription dermatological drugs market share, detailed prescription dermatological drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prescription dermatological drugs industry. This prescription dermatological drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The prescription dermatological drugs market size has grown strongly in recent years. It will grow from $37.77 billion in 2024 to $40.38 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to the increasing prevalence of skin disorders, greater awareness of skin health, the expansion of dermatology clinics, a growing geriatric population, rising healthcare expenditures, and increased investments in research and development.

The prescription dermatological drugs market size is expected to see strong growth in the next few years. It will grow to $52.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period is expected to be driven by the increasing prevalence of skin disorders, rising awareness of dermatological health, expanding telemedicine adoption for dermatology consultations, the growing demand for skincare aesthetics, enhanced insurance coverage for dermatological treatments, and the increasing focus on personalized medicine and precision dermatology. Key trends include the development of targeted biologic therapies, the adoption of gene editing for skin conditions, advancements in drug delivery systems, personalized treatments through genetic profiling, improved absorption in topical medications, and the integration of artificial intelligence to optimize drug formulations and treatment plans.

The growing prevalence of dermatological conditions is expected to drive the expansion of the prescription dermatological drugs market. Dermatological conditions encompass disorders affecting the skin, hair, or nails, such as eczema, psoriasis, and acne, which require medical treatment for effective symptom management. The increasing occurrence of these conditions is largely attributed to heightened exposure to environmental pollutants, lifestyle changes, and rising stress levels. Prescription dermatological drugs play a vital role in managing these conditions by providing targeted treatments to alleviate symptoms and promote long-term skin health. For example, in March 2022, Europe PubMed Central, a UK-based organization hosted by EMBL's European Bioinformatics Institute for biomedical research, reported that a study conducted across 27 European countries found that approximately 43.35% of participants equivalent to around 185 million individuals experienced at least one skin condition, with fungal infections, atopic dermatitis, and acne being the most prevalent. As a result, the increasing prevalence of dermatological conditions is fueling the growth of the prescription dermatological drugs market.

Leading companies in the prescription dermatological drugs market are prioritizing the development of innovative treatments, such as therapies for prurigo nodularis, to address unmet medical needs and provide more effective solutions for patients suffering from chronic and difficult-to-treat skin conditions. Prurigo nodularis is a chronic skin disorder characterized by intensely itchy, raised, and firm nodules or bumps on the skin. For instance, in September 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, partnered with Sanofi S.A., a France-based pharmaceutical company, to secure approval from the U.S. Food and Drug Administration (FDA) for Dupixent (dupilumab). This marks the first and only FDA-approved treatment for prurigo nodularis. The approval was based on clinical trial data demonstrating significant improvements in itch severity and skin lesions in patients treated with Dupixent compared to those receiving a placebo.

In October 2024, Organon & Co., a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for $1.2 billion. Through this acquisition, Organon aims to expand its dermatology portfolio by incorporating innovative treatments for chronic skin conditions, including prurigo nodularis and psoriasis. Dermavant Sciences Ltd. is a US-based company specializing in the development of therapeutic solutions in immunodermatology.

Major players in the prescription dermatological drugs market are Pfizer Inc., Johnson & Johnson, Merck KGaA, AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A/S, Glenmark Pharmaceuticals Limited, Almirall S.A., DermBiont Inc.

North America was the largest region in the prescription dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prescription dermatological drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prescription dermatological drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prescription dermatological drugs market consists of sales of products such as antifungals, antihistamines, and isotretinoin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prescription Dermatological Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prescription dermatological drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prescription dermatological drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prescription dermatological drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Class: Corticosteroids; Retinoids; Calcineurin Inhibitors; Antifungal Agents; Antibiotics; Other Drug Classes
  • 2) By Indication: Acne; Psoriasis; Dermatitis; Fungal Skin Infections; Other Indications
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
  • Subsegments:
  • 1) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids
  • 2) By Retinoids: Topical Retinoids; Oral Retinoids
  • 3) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors; Oral Calcineurin Inhibitors
  • 4) By Antifungal Agents: Topical Antifungals; Oral Antifungals
  • 5) By Antibiotics: Topical Antibiotics; Oral Antibiotics
  • 6) By Other Drug Classes: Immunosuppressants; Phototherapy Agents
  • Companies Mentioned:Pfizer Inc.; Johnson & Johnson; Merck KGaA; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prescription Dermatological Drugs Market Characteristics

3. Prescription Dermatological Drugs Market Trends And Strategies

4. Prescription Dermatological Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Prescription Dermatological Drugs Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Prescription Dermatological Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Prescription Dermatological Drugs Market Growth Rate Analysis
  • 5.4. Global Prescription Dermatological Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Prescription Dermatological Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Prescription Dermatological Drugs Total Addressable Market (TAM)

6. Prescription Dermatological Drugs Market Segmentation

  • 6.1. Global Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Corticosteroids
  • Retinoids
  • Calcineurin Inhibitors
  • Antifungal Agents
  • Antibiotics
  • Other Drug Classes
  • 6.2. Global Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Acne
  • Psoriasis
  • Dermatitis
  • Fungal Skin Infections
  • Other Indications
  • 6.3. Global Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
  • 6.4. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Corticosteroids
  • Oral Corticosteroids
  • Injectable Corticosteroids
  • 6.5. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Retinoids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Retinoids
  • Oral Retinoids
  • 6.6. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Calcineurin Inhibitors
  • Oral Calcineurin Inhibitors
  • 6.7. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Antifungal Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Antifungals
  • Oral Antifungals
  • 6.8. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Antibiotics
  • Oral Antibiotics
  • 6.9. Global Prescription Dermatological Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunosuppressants
  • Phototherapy Agents

7. Prescription Dermatological Drugs Market Regional And Country Analysis

  • 7.1. Global Prescription Dermatological Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Prescription Dermatological Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Prescription Dermatological Drugs Market

  • 8.1. Asia-Pacific Prescription Dermatological Drugs Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Prescription Dermatological Drugs Market

  • 9.1. China Prescription Dermatological Drugs Market Overview
  • 9.2. China Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Prescription Dermatological Drugs Market

  • 10.1. India Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Prescription Dermatological Drugs Market

  • 11.1. Japan Prescription Dermatological Drugs Market Overview
  • 11.2. Japan Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Prescription Dermatological Drugs Market

  • 12.1. Australia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Prescription Dermatological Drugs Market

  • 13.1. Indonesia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Prescription Dermatological Drugs Market

  • 14.1. South Korea Prescription Dermatological Drugs Market Overview
  • 14.2. South Korea Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Prescription Dermatological Drugs Market

  • 15.1. Western Europe Prescription Dermatological Drugs Market Overview
  • 15.2. Western Europe Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Prescription Dermatological Drugs Market

  • 16.1. UK Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Prescription Dermatological Drugs Market

  • 17.1. Germany Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Prescription Dermatological Drugs Market

  • 18.1. France Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Prescription Dermatological Drugs Market

  • 19.1. Italy Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Prescription Dermatological Drugs Market

  • 20.1. Spain Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Prescription Dermatological Drugs Market

  • 21.1. Eastern Europe Prescription Dermatological Drugs Market Overview
  • 21.2. Eastern Europe Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Prescription Dermatological Drugs Market

  • 22.1. Russia Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Prescription Dermatological Drugs Market

  • 23.1. North America Prescription Dermatological Drugs Market Overview
  • 23.2. North America Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Prescription Dermatological Drugs Market

  • 24.1. USA Prescription Dermatological Drugs Market Overview
  • 24.2. USA Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Prescription Dermatological Drugs Market

  • 25.1. Canada Prescription Dermatological Drugs Market Overview
  • 25.2. Canada Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Prescription Dermatological Drugs Market

  • 26.1. South America Prescription Dermatological Drugs Market Overview
  • 26.2. South America Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Prescription Dermatological Drugs Market

  • 27.1. Brazil Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Prescription Dermatological Drugs Market

  • 28.1. Middle East Prescription Dermatological Drugs Market Overview
  • 28.2. Middle East Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Prescription Dermatological Drugs Market

  • 29.1. Africa Prescription Dermatological Drugs Market Overview
  • 29.2. Africa Prescription Dermatological Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Prescription Dermatological Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Prescription Dermatological Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Prescription Dermatological Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Prescription Dermatological Drugs Market Competitive Landscape
  • 30.2. Prescription Dermatological Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Prescription Dermatological Drugs Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. GSK plc
  • 31.3. Amgen Inc.
  • 31.4. Teva Pharmaceutical Industries Ltd.
  • 31.5. Intas Pharmaceuticals Inc.
  • 31.6. Regeneron Pharmaceuticals Inc.
  • 31.7. Mylan NV
  • 31.8. Sun Pharmaceutical Industries Ltd.
  • 31.9. Cipla Limited
  • 31.10. Dr. Reddy's Laboratories Ltd.
  • 31.11. Zydus Cadila Health Care Limited
  • 31.12. Leo Pharma A/S
  • 31.13. Glenmark Pharmaceuticals Limited
  • 31.14. Almirall S.A.
  • 31.15. DermBiont Inc.

32. Global Prescription Dermatological Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Prescription Dermatological Drugs Market

34. Recent Developments In The Prescription Dermatological Drugs Market

35. Prescription Dermatological Drugs Market High Potential Countries, Segments and Strategies

  • 35.1 Prescription Dermatological Drugs Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Prescription Dermatological Drugs Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Prescription Dermatological Drugs Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer